• -
  • English
  • Japanese
  • Korean
表紙
市場調查報告書
商品編碼
808270

Dipeptidyl Peptidase4(DPP-4)抑制劑的全球市場 - 成長，趨勢，預測(2019年∼2024年)

DIPEPTIDE PEPTIDASE 4 (DPP-4) INHIBITORS MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)
出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 100 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球Dipeptidyl Peptidase4(DPP-4)抑制劑市場在2018年估算為105億美元，從2019年到2024年間預測將以4％的年複合成長率成長。

本報告提供全球Dipeptidyl Peptidase4(DPP-4)抑制劑市場調查，市場概要，各醫藥品類型、各地區的市場規模的變化與預測，市場成長要素及阻礙因素分析，競爭情形，主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 調查結果
  • 前提條件
  • 調查範圍

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 成長要素
  • 阻礙因素
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第5章 市場區隔

  • 各類醫藥品
    • Januvia (Sitagliptin)
    • Onglyza (Saxagliptin)
    • Tradjenta (Linagliptin)
    • Vipidia/Nesina (Alogliptin)
    • Galvus (Vildagliptin)
  • 各地區
    • 北美
    • 歐洲
    • 南美
    • 亞太地區
    • 中東、非洲

第6章 市場區隔

  • 第一型糖尿病的患者數
  • 第二型糖尿病的患者數

第7章 競爭情形

  • 企業簡介
    • Merck And Co.
    • AstraZeneca
    • Bristol Myers Squibb
    • Novartis
    • 武田藥品工業
    • Eli Lilly
    • Boehringer Ingelheim
  • 企業佔有率分析
    • Merck And Co.
    • AstraZeneca
    • 武田藥品工業
    • Novartis
    • Eli Lilly & Boehringer Ingelheim

第8章 市場機會與未來展望

目錄
Product Code: 62931

The global DPP-4 inhibitors market was valued at USD 10.5 billion in 2018, and is expected to record a CAGR of 4% during 2019-2024. The North American DPP-4 drugs segment of the market studied accounted for the highest revenue, in 2018, and Latin America is expected to register the highest CAGR, of approximately 6%, during the forecast period.

Key Highlights

  • Increasing diabetes type-2 and obesity populations will drive the growth of the market in the forecast period.
  • Increase in clinical trials on the DPP-4 drugs will also boost the market growth in the forecast period.

Key Market Trends

The Tradjenta Market will Surpass Merck's Januvia During the Forecast Period

The global Tradjenta market is expected to register a CAGR of 5.7 %, during the forecast period, 2019-2024, and is expected to surpass the Januvia market, which held the maximum market share in 2018. The Tradjenta market includes its combination Jentadueto and Jentadueto XR, a combination of linagliptin (Tradjenta) and metformin hydrochloride, for use in the treatment of type 2 diabetes. The type-2 diabetes drug, Tradjenta (linagliptin) was not launched in Germany, because of a decision by the county's reimbursement authority, which concluded that it doesn't provide any additional benefits, compared to the medicines already on the market.

North America Holds the Highest Market Share

  • North America holds 38% of the market share in the global DPP-4 market, followed by the Asia Pacific. Increasing diabetes prevalence in established and emerging countries is expected to drive the market. This increase, over the years, is due to the overall effect of individual-level factors, like an increasing median age of the population and health factors, including obesity and inactivity levels among people.
  • Lowering birth rates, along with increasing life expectancy in countries like Japan, Italy, Germany, and France, which have a high percentage of the geriatric population, are expected to drive the growth of the market.

Competitive Landscape

Merck held the highest market share in the DPP-4 market in 2018 and is expected to maintain its position till 2022. After that, it may witness a decline in market share, due to the expected launch of a generic version of Sitagliptin in 2022.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Drivers
  • 4.3 Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drug
    • 5.1.1 Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors (Value and Volume 2012-2024)
      • 5.1.1.1 Januvia (Sitagliptin)
      • 5.1.1.2 Onglyza (Saxagliptin)
      • 5.1.1.3 Tradjenta (Linagliptin)
      • 5.1.1.4 Vipidia/Nesina (Alogliptin)
      • 5.1.1.5 Galvus (Vildagliptin)
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States (Value and Volume, 2012-2024)
      • 5.2.1.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.1.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.1.2 Canada (Value and Volume, 2012-2024)
      • 5.2.1.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.1.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.1.3 Rest of North America (Value and Volume, 2012-2024)
      • 5.2.1.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.1.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
    • 5.2.2 Europe
      • 5.2.2.1 France (Value and Volume, 2012-2024)
      • 5.2.2.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.2.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.2.2 Germany (Value and Volume, 2012-2024)
      • 5.2.2.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.2.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.2.3 Italy (Value and Volume, 2012-2024)
      • 5.2.2.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.2.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.2.4 Spain (Value and Volume, 2012-2024)
      • 5.2.2.4.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.2.4.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.2.5 United Kingdom (Value and Volume, 2012-2024)
      • 5.2.2.5.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.2.5.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.2.6 Russia (Value and Volume, 2012-2024)
      • 5.2.2.6.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.2.6.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.2.7 Rest of Europe (Value and Volume, 2012-2024)
      • 5.2.2.7.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.2.7.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
    • 5.2.3 Latin America
      • 5.2.3.1 Mexico (Value and Volume, 2012-2024)
      • 5.2.3.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.3.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.3.2 Brazil (Value and Volume, 2012-2024)
      • 5.2.3.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.3.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.3.3 Rest of Latin America (Value and Volume, 2012-2024)
      • 5.2.3.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.3.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
    • 5.2.4 Asia-Pacific
      • 5.2.4.1 Japan (Value and Volume, 2012-2024)
      • 5.2.4.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.4.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.4.2 South Korea (Value and Volume, 2012-2024)
      • 5.2.4.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.4.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.4.3 China (Value and Volume, 2012-2024)
      • 5.2.4.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.4.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.4.4 India (Value and Volume, 2012-2024)
      • 5.2.4.4.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.4.4.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.4.5 Australia (Value and Volume, 2012-2024)
      • 5.2.4.5.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.4.5.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.4.6 Vietnam (Value and Volume, 2012-2024)
      • 5.2.4.6.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.4.6.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.4.7 Malaysia (Value and Volume, 2012-2024)
      • 5.2.4.7.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.4.7.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.4.8 Indonesia (Value and Volume, 2012-2024)
      • 5.2.4.8.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.4.8.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.4.9 Philippines (Value and Volume, 2012-2024)
      • 5.2.4.9.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.4.9.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.4.10 Thailand (Value and Volume, 2012-2024)
      • 5.2.4.10.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.4.10.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.4.11 Rest of Asia-Pacific (Value and Volume, 2012-2024)
      • 5.2.4.11.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.4.11.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
    • 5.2.5 Middle East & Africa
      • 5.2.5.1 Saudi Arabia (Value and Volume, 2012-2024)
      • 5.2.5.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.5.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.5.2 Iran (Value and Volume, 2012-2024)
      • 5.2.5.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.5.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.5.3 Egypt (Value and Volume, 2012-2024)
      • 5.2.5.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.5.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.5.4 Oman (Value and Volume, 2012-2024)
      • 5.2.5.4.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.5.4.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.5.5 South Africa (Value and Volume, 2012-2024)
      • 5.2.5.5.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.5.5.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.5.6 Rest of Middle East & Africa (Value and Volume, 2012-2024)
      • 5.2.5.6.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.5.6.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

6 MARKET INDICATORS

  • 6.1 Type-1 Diabetes Population (2012-2024)
  • 6.2 Type-2 Diabetes Population (2012-2024)

7 COMPETITIVE LANDSCAPE

  • 7.1 Company Profiles
    • 7.1.1 Merck And Co.
      • 7.1.1.1 Overview
      • 7.1.1.2 Products and Strategies
      • 7.1.1.3 Recent Development
    • 7.1.2 AstraZeneca
      • 7.1.2.1 Overview
      • 7.1.2.2 Products and Strategies
      • 7.1.2.3 Recent Development
    • 7.1.3 Bristol Myers Squibb
      • 7.1.3.1 Overview
      • 7.1.3.2 Products and Strategies
      • 7.1.3.3 Recent Development
    • 7.1.4 Novartis
      • 7.1.4.1 Overview
      • 7.1.4.2 Products and Strategies
      • 7.1.4.3 Recent Development
    • 7.1.5 Takeda Pharmaceuticals
      • 7.1.5.1 Overview
      • 7.1.5.2 Products and Strategies
      • 7.1.5.3 Recent Development
    • 7.1.6 Eli Lilly
      • 7.1.6.1 Overview
      • 7.1.6.2 Products and Strategies
      • 7.1.6.3 Recent Development
    • 7.1.7 Boehringer Ingelheim
      • 7.1.7.1 Overview
      • 7.1.7.2 Products and Strategies
      • 7.1.7.3 Recent Development
  • 7.2 Company Share Analysis
    • 7.2.1 Merck And Co.
    • 7.2.2 AstraZeneca
    • 7.2.3 Takeda Pharmaceuticals
    • 7.2.4 Novartis
    • 7.2.5 Eli Lilly & Boehringer Ingelheim

8 MARKET OPPORTUNITIES AND FUTURE TRENDS